Essex Junction, VT and Cleveland, OH, October 11, 2019 – Edgewater Capital Partners announced today that they have entered into an agreement to acquire Haematologic Technologies Incorporated, a leading provider of biologic products and GMP compliant assay development and testing services to the biopharmaceutical industry. The Company’s product line includes proteins, antibodies and associated reagents for thrombosis research and in-vitro diagnostic applications. Financial terms were not disclosed.

Founded in 1987 by Kenneth Mann, a prominent scientist in the field of thrombosis and hemostasis, Haematologic Technologies, Inc. (“HTI” or the “Company”) has established itself as the authority within the blood coagulation and protein chemistry fields, including deep expertise in the purification, characterization and testing of coagulation and plasma proteins. The Company has grown to become a leading provider of coagulation reagents and bioanalytical services through its focus in custom protein purification, protein modification, assay development, and GMP compliant stability and release testing. The Company’s services span early pre-clinical development through testing and release of commercial Biologics.

“HTI is extremely excited to partner with Edgewater as we enter our next phase of growth. We strive to continually serve our customers with our technical support, deep expertise in protein biochemistry, and strong focus on quality.” said Richard Jenny, President and Chief Executive Officer of Haematologic Technologies. “This partnership will greatly enhance our ability to achieve our goals and will further enhance our ability to produce innovative solutions for our clients. Together with Edgewater, we will focus on becoming a leading outsourced services partner to the biologics industry.”

“We are excited to have HTI join the Edgewater family and to support the next phase of the Company’s growth as they increasingly become a premier outsource partner for the biopharmaceutical industry. The business’ deep expertise and proven innovation in assay and method development for leading biopharmaceutical companies, coupled with a broad portfolio of products critical in blood diagnostics and biologic clinical trials, have positioned the Company as the leading authority in their area of focus. We are eager to build on this platform and to partner with the talented technical team at Haematologic Technologies,” said Robert Girton, Partner, Edgewater Capital.

About Haematologic Technologies

Haematologic Technologies, headquartered in Essex Junction, Vermont, is a leading provider of research reagents, customized blood collection tubes and protein biochemistry services including assay development, validation, and GMP release and stability testing.

With a strong protein biochemistry expertise and an emphasis on blood coagulation, the Company provides contract research and development services such as custom protein purification, protein modification, assay development, GMP stability and release testing, and offers over 150 high-quality blood coagulation products including proteins, antibodies, inhibitors and substrates, deficient plasmas, custom IVD/POC reagents, and custom blood/specimen collection tubes.

Additional information about Haematologic Technologies Incorporated is available at

About Edgewater Capital Partners

Edgewater Capital Partners, headquartered in Cleveland, Ohio, is a sector focused private equity firm dedicated to investing in lower middle-market performance materials businesses. Edgewater has extensive experience and expertise in specialty chemicals, life sciences, engineered components, and advanced materials. Twenty years of industry specific investing has allowed the Firm to develop a deep understanding of the complexities and nuances common to these businesses.

Additional information about Edgewater Capital Partners is available at